Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Neuronasal","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ATAI Life Sciences Announces Neuronasal Completes Pilot Study, Receives IND Clearance to Continue into Phase I Trials of mTBI Therapeutic","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling"},{"orgOrder":0,"company":"Neuronasal","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ATAI Life Sciences Partners with Neuronasal Inc. to Develop Novel Treatment for mild Traumatic Brain Injury (mTBI)","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed"},{"orgOrder":0,"company":"Auditus","sponsor":"Oblato","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oblato Biotech Company Acquires Hearing Loss Drug","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2020","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II"},{"orgOrder":0,"company":"Neuronasal","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neuronasal, Inc. Announces Completion of Pilot Study, Receives IND Clearance to Continue into Phase I Trials of mTBI Therapeutic","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling"},{"orgOrder":0,"company":"ImmunoFlex","sponsor":"Chemistree","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chemistree Investee ImmunoFlex Receives Health Canada Approval For Flex 10 Product","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"January 2021","url1":"","url2":"","graph1":"Immunology","graph2":"Approved"},{"orgOrder":0,"company":"Ashvattha Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ashvattha Therapeutics Announces Publication of Data in Science Translational Medicine from Phase 2a Clinical Trial for OP-101 in Severe COVID-19 Showing Significant Reduction in Inflammatory and Neuroinflammatory Markers and Improved Clinical Outcomes","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Kelso Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kelso Pharma Announces First Product Launch","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"January 2023","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Provides Update Evaluating Bucillamine for Nerve Agent Exposure with Defence Research and Development Canada","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"January 2024","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for N-Acetylcysteine

    Menu

    N-Acetylcysteine

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    DOSSIERs // Finished Dosage Forms

    DRUG PRODUCT COMPOSITION

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Revive Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Revive Therapeutics Provides Update Evaluating Bucillamine for Nerve Agent Exposure with Defence Research and Development Canada

              Details:

              Bucillamine is a potent antioxidant and anti-inflammatory, small molecule drug candidate. It is being evaluated for the treatment of nerve agent induced brain injury seizure.

              Lead Product(s): Bucillamine,Acetylcysteine

              Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 16, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Kelso Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Kelso Pharma Announces First Product Launch

              Details:

              Acepiro (acetylcysteine) a mucolytic agents which reduces bronchial secretion viscosity to facilitate expectoration for clearing the airways. It is indicated in adults for respiratory tract diseases treatment.

              Lead Product(s): Acetylcysteine

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Acepiro

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 30, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Ashvattha Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Ashvattha Therapeutics Announces Publication of Data in Science Translational Medicine from Phase 2a Clinical Trial for OP-101 in Severe COVID-19 Showing Significant Reduct...

              Details:

              Data showed OP-101 (N-acetyl Cysteine) delivered intravenously may have the potential to treat systemic inflammation and neuronal injury, reducing morbidity and mortality in hospitalized patients with severe COVID-19.

              Lead Product(s): Acetylcysteine

              Therapeutic Area: Infections and Infectious Diseases Product Name: OP-101

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 25, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ImmunoFlex

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Chemistree Investee ImmunoFlex Receives Health Canada Approval For Flex 10 Product

              Details:

              FLEX 10™ is ImmunoFlex's unique N-Acetyl-L-cysteine formulation in packs of 30 - 600 mg capsules. FLEX 10TM is a powerful antioxidant, specifically packaged in aluminum blisters to reduce the potential for product oxidation.

              Lead Product(s): Acetylcysteine

              Therapeutic Area: Immunology Product Name: FLEX 10

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Chemistree

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 19, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Neuronasal

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Neuronasal, Inc. Announces Completion of Pilot Study, Receives IND Clearance to Continue into Phase I Trials of mTBI Therapeutic

              Details:

              Neuronasal has been granted Investigational New Drug (IND) clearance by the U.S. Food and Drug Administration (FDA) to continue its plans for a Phase I clinical trial, and is doing so in partnership with ATAI Life Sciences.

              Lead Product(s): Acetylcysteine

              Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: ATAI Life Sciences

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 12, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Neuronasal

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ATAI Life Sciences Announces Neuronasal Completes Pilot Study, Receives IND Clearance to Continue into Phase I Trials of mTBI Therapeutic

              Details:

              Neuronasal's potentially ground-breaking proprietary treatment includes the intranasal delivery of low doses of N-acetylcysteine to patients with acute mild traumatic brain injury (mTBI). NAC has the potential to disrupt the deleterious chain of events following mTBI.

              Lead Product(s): Acetylcysteine

              Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: ATAI Life Sciences

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 21, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Auditus

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Country
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Oblato Biotech Company Acquires Hearing Loss Drug

              Details:

              Oblato assumes exclusive rights to a drug known as NHPN-1010. Oblato is expected to initiate a phase 2 clinical trial to evaluate the potential of the drug to prevent and treat hearing loss.

              Lead Product(s): Acetylcysteine,2,4-disulfonyl alpha-phenyl tertiary butyl nitrone

              Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Oblato

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement February 12, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Neuronasal

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ATAI Life Sciences Partners with Neuronasal Inc. to Develop Novel Treatment for mild Traumatic Brain Injury (mTBI)

              Details:

              The partners will develop a short-term treatment which includes intranasal delivery of low doses of N-acetylcysteine for mild Traumatic Brain Injury (mTBI) or concussion.

              Lead Product(s): Acetylcysteine

              Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Small molecule

              Partner/Sponsor/Collaborator: ATAI Life Sciences

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership January 06, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Axplora Acetylcysteine
              Basic Nutrition N Acetylcysteine
              Close
              4
              Post Enquiry
              POST ENQUIRY